Dota psma 617 precursor

¹⁷⁷Lu-PSMA-617 was obtained by radiolabeling of DOTA-PSMA-617 precursor (ABX GmbH, Radeberg, Germany) with no-carrier-added ¹⁷⁷LuCl₃ (ITG GmbH, Garching, Germany) as described previously [15 (link)]. ¹⁷⁷Lu-PSMA-617 was injected intravenously over 15–20 min using an infusion pump. Before and after therapy, all patients were hydrated with 2 liters of sodium-iodine. During and after therapy, all patients received cool packs to reduce the blood flow of the salivary glands.

DOTA-PSMA-617 precursor was obtained from ABX GmbH (Radeberg, Germany). In brief, DOTA-PSMA-617 was dissolved in 1.5 ml of acetate buffer (pH 4.8) containing 10 mg/ml dihydroxybenzoic acid. The solution was added to no-carrier-added ¹⁷⁷LuCl₃ in 0.04M HCl obtained from ITG GmbH (Garching, Germany), and heated for 30 min at 90 to 100°C. The amount of precursor was 20 μg/GBq ¹⁷⁷Lu. Radiochemical yield of ¹⁷⁷Lu-PSMA-617 was greater than 95% and radiochemical purities greater than 99% were achieved in each final PBS-buffered preparation. Each treatment was performed during a four days stay at the Nuclear Medicine ward. ¹⁷⁷Lu-PSMA-617 was given by slow i.v. application over twenty minutes. Patients received 50 mg prednisolone and 1L of 0.9% NaCl i.v. or equivalent amounts of p.o. fluids daily until discharge. In order to reduce blood flow and radioligand uptake in parotid and submandibular glands, ice packs were applied locally from ten min prior to ¹⁷⁷Lu-PSMA-617 administration, and continued for six hours thereafter.